Iterum Therapeutics
ITRM

$1.09

0%

Market Cap: $24.7M

About: Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Employees: 14

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

4.36% less ownership

Funds ownership: 6.96% [Q1] → 2.61% (-4.36%) [Q2]

17% less funds holding

Funds holding: 18 [Q1] → 15 (-3) [Q2]

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

66% less capital invested

Capital invested by funds: $1.44M [Q1] → $495K (-$944K) [Q2]

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$5

359%

upside

Avg. target

$5.33

389%

upside

High target

$6

450%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Ed Arce 43% 1-year accuracy 60 / 140 met price target	359%upside $5	Buy Reiterated	10 Sept 2024
HC Wainwright & Co. Ed Arce 43% 1-year accuracy 60 / 140 met price target	359%upside $5	Buy Maintained	15 Aug 2024
HC Wainwright & Co. Ed Arce 43% 1-year accuracy 60 / 140 met price target	450%upside $6	Buy Reiterated	21 Jun 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down

Iterum provides updates from the FDA's Antimicrobial Drugs Advisory Committee meeting on its NDA for oral sulopenem to treat adult women with uUTI.

ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down

Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference

DUBLIN, Ireland and CHICAGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today announced that Corey Fishman, Iterum's Chief Executive Officer, will present and host investor meetings at the 26th Annual H.C. Wainwright Global Investment Conference held September 9 to September 11, 2024, at the Lotte New York Palace Hotel.

Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference

Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript

Iterum Therapeutics plc (NASDAQ:ITRM ) Q2 2024 Results Conference Call August 14, 2024 8:30 AM ET Company Participants Louise Barrett - Senior Vice President of Legal Affairs & Secretary Corey Fishman - President, CEO & Director Judith Matthews - Chief Financial Officer Conference Call Participants Jason McCarthy - Maxim Group Operator Good morning, everyone. Welcome to Iterum Therapeutics Second Quarter 2024 Financial Results and Business Update.

Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript

Iterum Therapeutics Reports Second Quarter 2024 Financial Results

- - FDA PDUFA Action Date of October 25, 2024; Advisory Committee Meeting on September 9, 2024— - -Cash Runway into 2025, including through PDUFA Action Date-- --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (Iterum) a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2024.

Iterum Therapeutics Reports Second Quarter 2024 Financial Results

Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

DUBLIN and CHICAGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its second quarter 2024 financial results before the open of the U.S. financial markets on Wednesday, August 14, 2024. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business.

Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Iterum Therapeutics Announces Expiration and Results of Rights Offering

DUBLIN and CHICAGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the subscription period of its previously announced rights offering (the “Rights Offering”) expired at 5:00 p.m., Eastern Time, on August 6, 2024. As previously disclosed, the Company distributed, at no charge, subscription rights to the Company's shareholders and holders of warrants that had contractual rights to participate in the Rights Offering which were not waived (each, an “eligible warrant holder” and collectively, the “eligible warrant holders”) as of 5:00 p.m., Eastern Time, on July 16, 2024 (the “Record Date”).

Iterum Therapeutics Announces Expiration and Results of Rights Offering

Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem

DUBLIN and CHICAGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the United States Patent and Trademark Office (USPTO) has issued a notice allowance for two U.S. patents and the Canadian Intellectual Property Office (CIPO) has issued a Canadian patent, all related to sulopenem etzadroxil and probenecid (oral sulopenem).

Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem

Iterum Therapeutics Commences Rights Offering

DUBLIN and CHICAGO, July 22, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has commenced its previously disclosed rights offering (the “Rights Offering”).

Iterum Therapeutics Commences Rights Offering

Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the U.S. Food and Drug Administration (FDA) has determined that the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women will be taken to Advisory Committee, and in its communication, highlighted that the purpose of the Advisory Committee was to discuss a) antimicrobial stewardship issues raised by potential approval and subsequent use of what would be the first oral penem in the U.S.; and b) the most appropriate target patient population(s) for treatment of uUTI with sulopenem etzadroxil/probenecid. The proposed date for the Advisory Committee meeting is September 9, 2024.

Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

Oral Sulopenem NDA has been assigned a PDUFA action date of October 25, 2024 Oral Sulopenem NDA has been assigned a PDUFA action date of October 25, 2024

Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

See News Rankings